Loading clinical trials...
Loading clinical trials...
A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE EFFECTS OF TALAZOPARIB ON CARDIAC REPOLARIZATION IN PATIENTS WITH ADVANCED SOLID TUMORS
Conditions
Interventions
Talazoparib
Locations
19
United States
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
Bakersfield, California, United States
UCLA Hematology/Oncology - Burbank
Burbank, California, United States
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
Fullerton, California, United States
UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D.
Los Angeles, California, United States
Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California, United States
TRIO-US Central Administration
Los Angeles, California, United States
Start Date
October 13, 2016
Primary Completion Date
May 30, 2017
Completion Date
June 22, 2017
Last Updated
December 17, 2019
NCT05720117
NCT06898450
NCT06658951
NCT05719558
NCT05098132
NCT05101070
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions